Phase 2 B-NHL Clinical Trials
4 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–4 of 4 trials
Recruiting
Phase 1Phase 2
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Acute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaB-Non Hodgkin Lymphoma+2 more
National Cancer Institute (NCI)126 enrolled1 locationNCT05442515
Recruiting
Phase 1Phase 2
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
B-cell Non-Hodgkin Lymphoma (B-NHL)
Cellectis S.A.80 enrolled10 locationsNCT05607420
Recruiting
Phase 1Phase 2
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
AML (Acute Myelogenous Leukemia)Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
Tianjin Medical University General Hospital90 enrolled1 locationNCT06911710
Recruiting
Phase 2
Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL
CART TherapyB-NHL
Ruijin Hospital144 enrolled1 locationNCT06695013